Joined in 2023 
82 
63 About this deal
Where providers can arrange the fetal anomaly scan later within the recommended window and have a pathway to facilitate referrals for further investigations and options for pregnancy choices in a timely manner and within the required national timeframes. Ongoing audit of practice should be in place to monitor conformity. The screening pathway must be completed by 23 weeks plus 0 days.
Certificates of Good Standing (dated within three months of the application date) if regulated by another regulator. All denominators above exclude samples referred for genetic testing where the only indication for testing is an increased NT. FASP recommends all women who accept first trimester screening must have all components of the screening test completed - NT and biochemistry. Performance thresholdsThis standard provides assurance that screening is offered to everyone who is eligible and each individual who chooses to accept screening has a conclusive screening result. National performance of ST4a (see standard SCT-S05) in Q2 was 50.6%, higher than the previous quarter. The trend graph below shows England ST4a performance since the KPI was first published in Q1 2019 to 2020. Thresholds have not yet been set for this KPI. The proportion of pregnant women eligible for first trimester combined screening for Down’s syndrome (T21), Edwards’ syndrome (T18) and Patau’s syndrome (T13) for whom a conclusive screening result is available at the day of report. Rationale We calculate performance by dividing numerator by denominator and multiplying by 100 to give a percentage. You will need an mySRA account to be able to log in and complete the application. Make changes to your anti-money laundering authorisation
Date standard last updated: April 2018 FASP-S09: diagnosis or intervention: diagnostic tests fetal anomaly screening Description Personal details, work history, professional regulation, confirmation they have no open investigations or closed adverse regulatory or disciplinary decisions against them. National performance of FA2 in Q2 2021 to 2022 was 99.2%, slightly higher than the previous quarter. FA2 is collected 6 months (2 quarters) in arrears. The trend graph below shows that England FA2 performance has remained above the achievable threshold of 95% since 1 April 2017. Denominator: number of confirmed cytogenetic diagnoses of T21 following any result (higher or lower chance) from the quadruple test The 20-week screening scan is offered to screen for Edwards’ syndrome and Patau’s syndrome, and 11 physical conditions. Private screeningNIPT is now offered following a higher chance result (between 1 in 2 and 1 in 150) from either the combined or quadruple test in both singleton and twin pregnancies. This standard is now called FASP-S03: diagnosis or intervention: test turnaround time quantitative fluorescence-polymerase chain reaction ( QF-PCR).
Standard S08b excludes women with a suspected or confirmed fetal anomaly where the referral is to an obstetric ultrasound specialist locally for ongoing investigation and care (as clinically appropriate as per local pathway). The numerator and denominator include those completing the fetal anomaly scan from 18 weeks plus 0 days to 23 weeks plus 0 days of pregnancy. National performance of ST4a (see standard SCT-S05) in Q1 was 49.6%, higher than the previous quarter. The trend graph below shows England ST4a performance since the KPI was first published in Q1 2019 to 2020. Thresholds have not yet been set for this KPI.
We listened
Log in to mySRA to apply, go to start a new application Apply for approval of an entity as an authorised role holder All 142 screening services submitted data, including 50 services that reported zero couples at risk. These revised screening standards for the NHS fetal anomaly screening programme ( FASP) replace previous versions. They apply to data collected from 1 April 2022 unless stated otherwise in the document. National performance of NB2 (see standard NBS-S06) in Q1 was 2.2%, higher than the previous quarter. The trend graph below shows that England NB2 performance is above the acceptable threshold of 2%. NB2 is a KPI where a lower performance is better.
The combined test can be performed when the baby’s crown rump length ( CRL) is between 45.0mm and 84.0mm. This is between 11 +2 and 14 +1 weeks. The nuchal translucency ( NT) measurement is needed to calculate the chance result. The blood sample can be taken from 10 weeks. Timely referral (local and tertiary as clinically appropriate) when an anomaly is suspected or confirmed. Due to COVID-19, during the Q1 (April to June 2020) time period newborn screening laboratories were instructed to relax blood spot acceptance criteria on samples that would normally have been rejected and to accept day 4 samples. Together these factors are likely to explain the reduced ‘avoidable repeat’ rate observed during Q1 2020 to 2021. Eligible women is the number of pregnant women booked for antenatal care during the reporting period, excluding women who: National performance of ID1 in Q1 was 99.7%. The national trend graph below shows that ID1 performance has remained above the achievable threshold of 99% since 1 April 2017.Guidance is available on the FASP programme’s processes for ensuring seamless and safe screening across the whole pathway. Denominator: number of samples received for QFPCR testing where the indication for genetic testing is a suspected or confirmed anomaly detected on the 18 weeks plus 0 days to 20 weeks plus 6 days fetal anomaly ultrasound undertaken in the reporting period. There is no intention to publish FA3 (see standard FASP-S01) by individual maternity service. We are reviewing the data with the aim of publishing it nationally in the future. Numerator: number of confirmed cytogenetic diagnoses of T21 following a higher chance T21 result from the combined test
Great Deal 
New Comment